OverviewSuggest Edit

BioNanomatrix develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The Company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications. 
TypePublic
Founded2002
HQSan Diego, CA, US
Websitebionanogenomics.com
Employee Ratings3.9
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2018)77(+19%)
Revenue (FY, 2019)$10.1 M(-15%)
Share Price (Mar 2021)$9.8 (+2%)
Cybersecurity ratingBMore

Key People/Management at BioNano Genomics

Erik Holmlin

Erik Holmlin

President, Chief Executive Officer & Director
David L. Barker

David L. Barker

Chairman
Mark Oldakowski

Mark Oldakowski

Chief Operating Officer
Christopher J. Twomey

Christopher J. Twomey

Director
Christopher Stewart

Christopher Stewart

Chief Financial Officer
Albert Luderer

Albert Luderer

Director
Show more

BioNano Genomics Office Locations

BioNano Genomics has offices in San Diego and London
San Diego, CA, US (HQ)
9640 Towne Centre Dr #100
London, GB
90 Fetter Ln, Holborn
Show all (2)

BioNano Genomics Financials and Metrics

BioNano Genomics Revenue

Embed Graph
View revenue for all periods
BioNano Genomics's revenue was reported to be $10.13 m in FY, 2019
USD

Revenue (Q2, 2020)

940.0k

Gross profit (Q2, 2020)

425.0k

Gross profit margin (Q2, 2020), %

45.2%

Market capitalization (1-Mar-2021)

2.7b

Closing stock price (1-Mar-2021)

9.8

Cash (30-Jun-2020)

17.2m

EV

2.7b
BioNano Genomics's current market capitalization is $2.7 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

6.8m9.5m12.0m10.1m

Revenue growth, %

40%

Cost of goods sold

3.6m6.0m8.7m6.8m

Gross profit

3.2m3.5m3.3m3.4m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.8m1.9m2.2m3.3m1.1m940.0k

Cost of goods sold

3.1m1.1m1.6m2.4m856.0k515.0k

Gross profit

(239.6k)705.7k619.4k937.9k280.0k425.0k

Gross profit Margin, %

(8%)38%28%28%25%45%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.2m1.0m16.5m17.3m

Accounts Receivable

1.8m3.4m4.5m6.3m

Prepaid Expenses

1.8m1.1m919.5k1.2m

Inventories

1.8m1.7m1.1m3.4m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

20.7m20.8m15.3m8.2m8.1m17.2m

Accounts Receivable

4.0m4.1m5.0m6.0m4.1m3.2m

Prepaid Expenses

1.3m1.7m631.9k1.0m1.1m921.0k

Inventories

2.6m1.4m3.0m2.6m3.6m3.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.8m)(23.4m)(18.5m)(29.8m)

Depreciation and Amortization

1.1m1.5m1.3m1.1m

Inventories

(726.1k)(336.0k)(419.0k)(3.6m)

Accounts Payable

(608.7k)1.5m(954.4k)1.4m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(12.1m)(7.9m)(15.5m)(21.9m)(10.5m)(18.6m)

Depreciation and Amortization

1.2m269.8k536.8k815.0k296.0k591.0k

Inventories

(2.1m)(337.3k)(2.0m)(1.9m)(635.0k)(1.0m)

Accounts Payable

60.8k(510.5k)2.3m1.0m477.0k150.0k
USDFY, 2016

Debt/Equity

-3.6 x

Debt/Assets

0.4 x

Financial Leverage

-8 x
Show all financial metrics

BioNano Genomics Acquisitions / Subsidiaries

Company NameDateDeal Size
LineagenAugust 24, 2020
BioNano Genomics (Shanghai) Trading Co.
BioNano Genomics UK

BioNano Genomics Revenue Breakdown

Embed Graph

BioNano Genomics revenue breakdown by geographic segment: 46.5% from Asia Pacific, 13.5% from EMEIA and 40.0% from North America

BioNano Genomics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

BioNano Genomics Online and Social Media Presence

Embed Graph

BioNano Genomics Company Culture

  • Overall Culture

    A+

    95/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

BioNano Genomics News and Updates

Thinking about buying stock in Durect Corp, T2 Biosystems, Gevo Inc, BioNano Genomics, or Advanced Micro Devices?

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRRX, TTOO, GEVO, BNGO, and AMD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Bionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock

SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 33,333,350 shares of its common stock at a price to the public of $6.00 per share. The gross proceeds to Bionano from the offe…

Bionano Genomics to sell more shares, stock falls

Bionano Genomics Inc. on Tuesday announced its second share sale in less than a month amid an unexplained spike in its price and volume, sending shares down in after-hours trading. Bionano did not disclose a targeted number of shares nor price in its offering, but the stock still fell more than 8% …

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on …

Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyr’s Utility in Genome Analysis for Genetic Disease and Cancer

SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the kick-off its 5-day Next-Generation Cytogenomics Symposium, which starts Monday January 11 and will feature 33 presentations by distinguished Saphyr users from leading hospitals and medical research ins…

Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share

Bionano Genomics Inc. said Friday it has priced an underwritten public offering of 29 million shares at $3.05 a share. The stock closed Thursday at $5.00. The genome analysis company has granted the underwriters -- Oppenheimer & Co., which is sole bookrunner, while BTIG acted as lead manager an…
Show more

BioNano Genomics Frequently Asked Questions

  • When was BioNano Genomics founded?

    BioNano Genomics was founded in 2002.

  • Who are BioNano Genomics key executives?

    BioNano Genomics's key executives are Erik Holmlin, David L. Barker and Mark Oldakowski.

  • How many employees does BioNano Genomics have?

    BioNano Genomics has 77 employees.

  • What is BioNano Genomics revenue?

    Latest BioNano Genomics annual revenue is $10.1 m.

  • What is BioNano Genomics revenue per employee?

    Latest BioNano Genomics revenue per employee is $131.6 k.

  • Who are BioNano Genomics competitors?

    Competitors of BioNano Genomics include BaseHealth, Bone Therapeutics and SiDx.

  • Where is BioNano Genomics headquarters?

    BioNano Genomics headquarters is located at 9640 Towne Centre Dr #100, San Diego.

  • Where are BioNano Genomics offices?

    BioNano Genomics has offices in San Diego and London.

  • How many offices does BioNano Genomics have?

    BioNano Genomics has 2 offices.